Navigation Links
Delayed access to tertiary care associated with higher death rate from type of pulmonary fibrosis
Date:7/1/2011

  • Patients with a form of pulmonary fibrosis often do not get referred to a tertiary care center quickly.

  • Delayed access is associated with a higher death rate.

  • Better methods of early detection would shorten time from first symptoms to referral.

(NEW YORK, NY, July 1, 2011) Idiopathic pulmonary fibrosis (IPF)―scarring and thickening of the lungs from unknown causes―is the predominant condition leading to lung transplantation nationwide. Columbia University Medical Center researchers confirmed that delayed access to a tertiary care center for IPF is associated with a higher risk of death. The findings were published online in the American Journal of Respiratory and Critical Care Medicine on June 30, 2011.

A group led by Columbia researcher David J. Lederer followed 129 IPF patients at an academic medical center. They looked at the length of time from the onset of shortness of breath to the first visit to the center. A longer delay was associated with increased risk of death, independent of age, gender, socioeconomic status, lung capacity, disease severity, type of health insurance, or education. The researchers also found no association between the length of delay and the likelihood of the patient's receiving a lung transplant.

IPF leads to respiratory failure and death, usually within three years. It is a relatively rare disease, which afflicts 100,000�,000 Americans, almost all over the age of 50. Characterized by shortness of breath upon exertion, it is often misdiagnosed, especially in people with other ailments.

A delay in making a correct diagnosis can lead to ineffective, or even harmful, treatments. For example, doctors sometimes still treat IPF with steroids, because the disease was originally thought to have an inflammatory component. Now scientists know that steroids are counterproductive. A delay in diagnosis can also delay evaluation for a lung transplant. Although research is underway on potential drug therapies, currently lung transplantation is the only effective treatment.

"The initial symptoms of IPF are subtle, and accurate diagnosis may not be feasible for community-based pulmonologists," explains Lederer, Herbert Irving Assistant Professor of Clinical Medicine and co-director of the New York-Presbyterian Hospital Interstitial Lung Disease Program and Lung Transplant Program.

For that reason, earlier access would be aided by improved methods of early detection. But until then, the recognition, or even suspicion, of IPF should prompt referral to a tertiary care center.


'/>"/>

Contact: Ann Rae Jonas
arj2116@columbia.edu
212-305-6535
Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. Taking Chemo Drug Continuously Delayed Lung Cancers Return
2. Common insecticide used in homes associated with delayed mental development of young children
3. Study shows delayed-enhancement MRI may predict, prevent strokes
4. Denosumab delayed time to first skeletal-related side effect
5. For HIV-positive patients, delayed treatment a costly decision
6. New study confirms positive effects of delayed school start times
7. $18.5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C-Section
8. Delayed retirement among Americans may bolster future of Social Security and Medicare, study finds
9. Pain Relief Often Delayed for Cancer Patients
10. Improving access to essential medicines through public-private partnerships
11. Clemson University research team to lead accessible voting technology project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent ... for drugs, biologics and consumer health products, today announced that it had joined ... 2006 as a non-profit organization to unite pharmaceutical and healthcare companies that share ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... 08, 2016 , ... Today’s patients are encouraged to be ... SIGVARIS has created a new line of anti-embolism stockings to help prevent a ... benefits of graduated compression when transitioning from recovery to early rehabilitation. , The ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital health ... led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and ... to serve more consumers who are managing chronic conditions or simply want ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... from offices headquartered in Hamilton County, is embarking on a charity drive with ... in finding new homes for orphaned or neglected senior dogs in the Cincinnati ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , 8. Dezember 2016 Mederi Therapeutics Inc . hat die ... nicht-operative Behandlungsmethode für gastroösophageale Refluxerkrankung (GERD) – in China ... ... Live Stretta procedure performed ... Liu, Director of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... 2016 Research and Markets has announced the ... offering. ... The global chromatography market to grow at a CAGR ... 2016-2020, has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
(Date:12/8/2016)... ALBANY, New York , December 8, 2016 ... the global Diabetes Injection Pens Market is expected ... as compared to US$4.9 bn in 2015. Between the forecast ... to rise at a CAGR of 7.9%. The leading players ... Nordisk A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., ...
Breaking Medicine Technology: